712 related articles for article (PubMed ID: 15551738)
1. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
2. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
Wang BY; Gil J; Kaufman D; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2002 Sep; 33(9):921-6. PubMed ID: 12378518
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of p63 expression in lung cancer by use of complementary DNA and tissue microarray].
Yu YW; Garber ME; Schlüns K; Pacyna-Gengelbach M; Petersen I
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):324-7. PubMed ID: 15363316
[TBL] [Abstract][Full Text] [Related]
4. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
Pelosi G; Pasini F; Olsen Stenholm C; Pastorino U; Maisonneuve P; Sonzogni A; Maffini F; Pruneri G; Fraggetta F; Cavallon A; Roz E; Iannucci A; Bresaola E; Viale G
J Pathol; 2002 Sep; 198(1):100-9. PubMed ID: 12210069
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
[TBL] [Abstract][Full Text] [Related]
6. p63 immunostaining in destained bronchoscopic cytological specimens.
Shtilbans V; Szporn AH; Wu M; Burstein DE
Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365
[TBL] [Abstract][Full Text] [Related]
7. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases.
Wang TY; Chen BF; Yang YC; Chen H; Wang Y; Cviko A; Quade BJ; Sun D; Yang A; McKeon FD; Crum CP
Hum Pathol; 2001 May; 32(5):479-86. PubMed ID: 11381365
[TBL] [Abstract][Full Text] [Related]
8. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
9. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
10. Role of p63 amplification and overexpression in lung cancer development.
Massion PP; Taflan PM; Rahman SM; Yildiz P; Shyr Y; Carbone DP; Gonzalez AL
Chest; 2004 May; 125(5 Suppl):102S. PubMed ID: 15136437
[No Abstract] [Full Text] [Related]
11. Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.
Hechtman JF; Beasley MB; Kinoshita Y; Ko HM; Hao K; Burstein DE
Hum Pathol; 2013 Jul; 44(7):1400-5. PubMed ID: 23416030
[TBL] [Abstract][Full Text] [Related]
12. p63 expression in normal skin and usual cutaneous carcinomas.
Reis-Filho JS; Torio B; Albergaria A; Schmitt FC
J Cutan Pathol; 2002 Oct; 29(9):517-23. PubMed ID: 12358808
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
Jiang SX; Kameya T; Sato Y; Yanase N; Yoshimura H; Kodama T
Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
16. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not.
Findeis-Hosey JJ; Huang J; Li F; Yang Q; McMahon LA; Xu H
Hum Pathol; 2011 Jun; 42(6):867-72. PubMed ID: 21292308
[TBL] [Abstract][Full Text] [Related]
17. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
18. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
Smith SL; Gugger M; Hoban P; Ratschiller D; Watson SG; Field JK; Betticher DC; Heighway J
Br J Cancer; 2004 Oct; 91(8):1515-24. PubMed ID: 15467767
[TBL] [Abstract][Full Text] [Related]
19. Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease.
Bir F; Aksoy Altınboga A; Satiroglu Tufan NL; Kaya S; Baser S; Yaren A
Med Sci Monit; 2014 Feb; 20():219-26. PubMed ID: 24509874
[TBL] [Abstract][Full Text] [Related]
20. Abnormal p53 expression in lung neuroendocrine tumors. Diagnostic and prognostic implications.
Roncalli M; Doglioni C; Springall DR; Papotti M; Pagani A; Polak JM; Ibrahim NB; Coggi G; Viale G
Diagn Mol Pathol; 1992 Jun; 1(2):129-35. PubMed ID: 1364172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
